The global female fertility drugs market size valued $3.28 billion in 2020 expected to reach $6.4 billion in 2027, at a CAGR of 6.3% during forecast period 2021-2027. Female fertility drugs are the agents used to improve the reproductive health in the women and act stimulating the follicle development of ovary. Women fertility drugs are extremely effective and first treatment option to overcome the infertility. Fertility drugs act by direct stimulation of ovaries or balancing the hormone levels. Infertility in women is occur due to hypothalamic dysfunction, excessive prolactin, pelvic inflammatory diseases, premature ovarian insufficiency, and polycystic ovary syndrome among others. The major symptom associated with the infertility is absence or irregular menstrual cycle. female fertility drugs market is growing at a significant CAGR with several local and international players operating in the infertility treatment. The prevalence of infertility is increasing due to change in lifestyle such as smoking and alcohol consumption. According to World Health Organization, approximately 60-80 Mn couples are suffering from infertility around the world. Moreover, acquisitions & mergers, collaborations, product approvals and product launchings are the strategies followed by the companies for increasing their market revenue share in female fertility drugs market. For instance, in March 2014, Ferring Pharmaceuticals received FDA approval for the combination of Menopur and Bravelle injection used in the treatment of infertility.